Description
The American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium 2013
- You cannot add another "Article: Clinically meaningful survival benefit with atezolizumab + nab-paclitaxel in previously untreated patients with PD-L1+ metastatic triple negative breast cancer" to your cart. View cart
Article: The American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium 2013
€3.03
Related products
-
Article: Updated results of the phase III COLUMBUS trial further solidify BRAF/MEK combinations as standard of care for BRAF-mutated advanced melanoma
€3.03 Add to cart -
Article: Highlights in gynaecological cancers
€3.03 Add to cart -
Article: Highlights in respiratory oncology
€3.03 Add to cart -
Article: Highlights in urologic cancer
€3.03 Add to cart
Reviews
There are no reviews yet.